NeuroOne (NASDAQ: NMTC) officer sells 13,720 shares around $0.80

Rhea-AI Filing Summary

NEUROONE MEDICAL TECHNOLOGIES Corp officer Mark Christianson reported open-market sales of a total of 13,720 shares of common stock at weighted average prices around $0.80 per share on March 10–11, 2026. After these transactions, he directly holds 215,200 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Christianson Mark

(Last) (First) (Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Business Development Director

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		S		11,611	D	$0.8(1)	217,309	D
Common Stock	03/11/2026		S		2,109	D	$0.8(2)	215,200	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $0.80 and 0.8102 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.

2. The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $0.80 and 0.805 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.

	/s/ Emily Johns, by Power of Attorney	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NMTC officer Mark Christianson report?

Mark Christianson reported selling 13,720 NMTC common shares in open-market transactions. The sales occurred on March 10 and 11, 2026, at weighted average prices around $0.80 per share, as disclosed in the Form 4 insider filing.

At what prices did NMTC shares sell in Mark Christianson’s Form 4?

The reported NMTC share sales used weighted average prices of about $0.80 per share. Footnotes state the individual trades ranged between $0.80 and approximately $0.8102, and between $0.80 and $0.805 per share across the multiple transactions.

How many NMTC shares does Mark Christianson own after these sales?

After the reported transactions, Mark Christianson directly owns 215,200 NMTC common shares. This figure reflects his remaining position following the total sale of 13,720 shares disclosed across the two open-market transactions in the Form 4 filing.

Over how many days were the NMTC insider sales by Mark Christianson made?

The NMTC insider sales were executed over two days, March 10 and March 11, 2026. Separate Form 4 line items show 11,611 shares sold on March 10 and 2,109 shares sold on March 11 in open-market transactions.

What role does Mark Christianson hold at NEUROONE MEDICAL TECHNOLOGIES (NMTC)?

Mark Christianson is an officer of NEUROONE MEDICAL TECHNOLOGIES Corp, serving as Business Development Director. His status as an officer requires reporting his trades in company stock on Form 4, including the March 2026 open-market sales of NMTC common shares.

Do the NMTC insider sales footnotes mention weighted average pricing?

Yes. The footnotes explain each reported line uses a weighted average sale price. They clarify that individual trades occurred in price ranges between $0.80 and $0.8102, and between $0.80 and $0.805 per share, with full trade details available upon request.